Fortress Biotech, Inc. (FBIOP) Net margin 2016–2025
Fortress Biotech, Inc. (FBIOP) net profit margin by fiscal year — reported net income divided by reported revenue.
10.8%FY2025 · since FY2016: -334.3% → 10.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 10.8% | +90.5 pp |
| FY2024 | -79.8% | -8.0 pp |
| FY2023 | -71.7% | +42.6 pp |
| FY2022 | -114.3% | -20.2 pp |
| FY2021 | -94.1% | +8.0 pp |
| FY2020 | -102.0% | +7.1 pp |
| FY2019 | -109.1% | +203.9 pp |
| FY2018 | -313.0% | +74.8 pp |
| FY2017 | -387.8% | -53.5 pp |
| FY2016 | -334.3% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More FBIOP financial trends
FBIOP RevenueFBIOP Net incomeFBIOP Gross profitFBIOP Gross marginFBIOP Operating incomeFBIOP Operating marginFBIOP Operating cash flowFBIOP Free cash flowFBIOP Capital expendituresFBIOP Return on equityFBIOP Stock buybacksFBIOP Dividends paidFBIOP Total assetsFBIOP Total liabilitiesFBIOP Shareholders’ equityFBIOP overview →